Here's exactly how it works, what the science does and doesn't yet show, and how it's used safely under medical supervision
As monotherapy , a multicentre, randomised, double-blind, placebo-controlled and active-controlled Phase 2 dose-finding trial enrolled 706 adults with overweight or obesity (without diabetes) to once-weekly subcutaneous cagrilintide across doses of 0.3 to 4.5 mg over 26 weeks
demonstrated dose-dependent proliferation effects on cultured human dermal papilla cells exposed to GHK-Cu at physiologically relevant concentrations.3 Subsequent work has confirmed that this effect translates into upregulation of genes associated with anagen-phase activity including VEGF, FGF-2, and IGF-1, the three growth factors most directly implicated in hair-cycle regulation
When you purchase retatrutide from UK SARMs, you can be confident in the reliability, reproducibility, and integrity of your research findings